Pharmacoeconomics

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 16, 2023
Neutropenia, Carcinoma, Medical Affairs Bureau, Providence St. Joseph Health, G1 Therapeutics, EMR, ISPOR, Pharmacoeconomics, Aplastic anemia, Patient, SCLC, RESEARCH, Bone marrow suppression, Risk, ECOG, Anemia, Diagnosis, Poster, Cornerstone, Therapy, Death, Thrombocytopenia, International Society, PARK, Medical imaging

“Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.

Key Points: 
  • “Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.
  • The poster, titled, “An Analysis of Patient Characteristics Associated With Myelosuppression Among Small Cell Lung Cancer Patients Treated in US Community Cancer Care Practices” is available in the scientific publications section of G1’s website.
  • Adult patients diagnosed with SCLC who received chemotherapy between 2016 and 2018 and had longitudinal laboratory data were included in this study.
  • In addition, multivariate logistic regressions were conducted to examine association between patient characteristics and risk of myelosuppression in each lineage (anemia, neutropenia, thrombocytopenia).

Fujitsu conducts project with Takeda and National Cancer Center Japan to analyze and visualize of patient journey with ovarian cancer

Retrieved on: 
Friday, May 12, 2023
Insurance, Comment, Health, Takeda, ISPOR, Health Level 7, Takeda Pharmaceutical Company, Cancer, Research, Pharmacoeconomics, Organization, Platform, Patient, Physician, Data, Division, Informatics, National Cancer Center, Diagnosis, AI, HL7, Ovarian cancer, Environment, International Society, Pharmaceutical industry, Nursing, Medical imaging, Fujitsu

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.

Key Points: 
  • These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.
  • This study was conducted based on a joint research agreement that Fujitsu concluded with Takeda and the National Cancer Center Japan in May 2021 with the aim of identifying clinical challenges that will contribute to improving the quality and therapeutic efficacy of personalized ovarian cancer treatment.
  • In the future, the platform will be able to extract patient medical data and convert it into HL7 FHIR(2).
  • It includes electronic medical record data, medical accounting data, health checkup data, patient registry data, and data obtained from wearable devices.

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

Retrieved on: 
Wednesday, May 10, 2023
Heart failure, Prevalence, Diabetes, Hospital, ISPOR, LVEF, NDA, Pharmacoeconomics, Life expectancy, Patient, Risk, PDUFA, Lexicon Pharmaceuticals, International Society, Satellite navigation device, Pharmaceutical industry

THE WOODLANDS, Texas, May 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results of a new investigator-initiated economic analysis, based on results from the SOLOIST-WHF Phase 3 outcomes study of its investigational medicine sotagliflozin, were presented on May 9 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Boston, Massachusetts.

Key Points: 
  • The researchers determined that sotagliflozin is a clinically and economically attractive medication and is cost-effective at commonly accepted willingness-to-pay thresholds in patients with diabetes and worsening heart failure.
  • Heart failure is the leading cause of hospitalization for Americans over the age of 65.
  • Patients with heart failure are at highest risk of having a repeat heart failure event in the first 30 days post-discharge, with 7% dying and 25% being rehospitalized within one month.
  • Lexicon’s NDA for sotagliflozin for the treatment of heart failure is on track for its May 27, 2023 PDUFA action date.

SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women

Retrieved on: 
Wednesday, May 10, 2023
Research, Infectious Diseases, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, AMN, Hospital, Liver disease, ISPOR, AAN, Woman, American Academy, Pharmacy, Pharmacoeconomics, AAV, Standard of care, Patient, American Academy of Neurology, Therapy, Death, Moyamoya disease, International Society, Pharmaceutical industry, Health insurance, Medicare

SwanBio Therapeutics , a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.

Key Points: 
  • SwanBio Therapeutics , a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.
  • Adults with AMN experienced more comorbidities, including peripheral vascular disease (men: 4.6% vs. 0.9%; women: 2.2% vs. 0.5%), chronic pulmonary disease (men: 6.3% vs. 2.6%; women: 6.0% vs. 3.6%), and liver disease (men: 5.6% vs. 0.8%; women: 3.2% vs. 0.9%).
  • A significantly larger proportion of people living with AMN had at least one hospital admission (men: 32.0% vs. 6.1%; women: 23.2% vs. 7.2%).
  • Men living with AMN also utilized significantly more prescription medications (18.1 vs. 5.4 pharmacy fills per year).

Komodo Health Platform Powers 17 Cutting-Edge Health Economics and Outcomes Research Presentations at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Software, Research, Professional Services, Pharmaceutical, Data Management, Venture Capital, Technology, Hospitals, Artificial Intelligence, Health Technology, Science, Health, Komodo, Duke University, Depression, ISPOR, COVID-19, Haemophilia, Genomics, Multiple sclerosis, Pharmacoeconomics, DSM-IV codes, Patient, Novo Nordisk, Janssen Pharmaceuticals, Mab, RWE, Government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, International Society, Food, Prostate cancer, Pharmaceutical industry, Medical imaging

Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.

Key Points: 
  • Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.
  • Together, researchers representing Komodo Health, its customers, and its partners will present the results of research analyzing clinical and economic value across a wide range of therapeutic areas, including COVID-19, multiple sclerosis, prostate cancer, and more.
  • “The world’s top Life Sciences research teams are increasingly turning to Komodo’s Healthcare Map and real-world evidence applications to power their research strategies,” said Usha Periyanayagam, Head of Research and Analytics at Komodo Health.
  • Within the Komodo platform, users can perform comprehensive analytics, develop predictive models, and employ custom workflows to unlock a range of patient-centric insights.

Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mental toughness, Partnership, Cognito, Health policy, ISPE, ISPOR, Deficit spending, Research, Pharmacoeconomics, MCI, CNS, Aetion, Patient, Risk, Amnesia, Diagnosis, AD, Therapy, Summit, International Society for Pharmacoepidemiology, International Society, Disease, Pharmaceutical industry

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.
  • The Summit is co-located with and being held immediately prior to the Society’s annual international conference, ISPOR 2023 .
  • The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy.
  • ISPOR is a leading professional society for health economics and outcomes research.

Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Bronchiolitis, Drug utilization review, SLT, ISPOR, BOS, DLT, CMO, Life expectancy, HSCT, Pharmacoeconomics, Lung transplantation, HIV disease progression rates, Patient, Disease, Health, Hematopoietic stem cell transplantation, Pharmaceutical industry, Zambon

The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).

Key Points: 
  • The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).
  • The study showed that BOS patients have significant morbidity leading to reduced life expectancy and high direct medical expenses.
  • The average lifetime cost of BOS patients was $83,500 ranging from $27,900 to $96,900 across all sub-types.
  • Details about the 2023 ISPOR Meeting presentation are as follows:
    For more information on ISPOR's program, please visit the conference website at https://www.ispor.org/conferences-education/conferences/upcoming-confere...

Implantica publishes Year-end Report, January - December 2022 (Q4)

Retrieved on: 
Friday, February 17, 2023
CFO, Insurance, Ethics committee, Ethics, GHP, Magnetism, Hospital, AKH, Nissen fundoplication, Patient, Medtech, News, ISPOR, EFS, AFS, Pharmacoeconomics, International Society, PPI, Corporate Affairs, Conference, Nursing, Pharmaceutical industry, Mobile phone

Implantica receives Global Health & Pharma's Award; Most Innovative MedTech Company- Central Europe for 2022 based on a serious due diligence by GHP, identifying the high innovation level of Implantica.

Key Points: 
  • Implantica receives Global Health & Pharma's Award; Most Innovative MedTech Company- Central Europe for 2022 based on a serious due diligence by GHP, identifying the high innovation level of Implantica.
  • Implantica attended the European Foregut Society (EFS) Conference in Belgrade, Serbia where the positive clinical outcomes of RefluxStop were presented by Dr. med.
  • Implantica presented RefluxStop's health economic impact at one of the biggest Payer conferences, ISPOR, the International Society for Pharmacoeconomics and Outcomes Research Conference in Vienna, Austria.
  • Implantica will hold a teleconference with Peter Forsell (CEO), Andreas Öhrnberg (CFO) and Nicole Pehrsson (Chief Corporate Affairs Officer).

Implantica publishes Interim Report Q3 2022

Retrieved on: 
Tuesday, November 15, 2022
2021 Essex County Council election, Conference, University of York, ICER, GHP, GERD, Awareness, News, Nissen fundoplication, Pharmacoeconomics, EFS, University, Reuters - The World's Most Innovative Universities, Standard of care, PPI, Insurance, Magnetism, Investment, Patient, Hospital, EUR, Gastroesophageal reflux disease, International Society, Pharmaceutical industry

Implantica initiated a therapy awareness project to enhance the patient, physician and caregiver's awareness about gastroesophageal reflux disease (GERD) and anti-reflux surgery.

Key Points: 
  • Implantica initiated a therapy awareness project to enhance the patient, physician and caregiver's awareness about gastroesophageal reflux disease (GERD) and anti-reflux surgery.
  • Implantica receives Global Health & Pharma's Most Innovative MedTech Company Central Europe Award for 2022 based on a serious due diligence by GHP, identifying the high innovation level of Implantica.
  • Implantica attended the European Foregut Society (EFS) Conference in Belgrade, Serbia where the good clinical outcomes of RefluxStop were presented by Dr. med.
  • Implantica will hold a telephone conference on November 15 at 15:00 CET.

Implantica Presents RefluxStop's Health Economic Impact at ISPOR Europe 2022

Retrieved on: 
Thursday, November 10, 2022
Quality of life, GERD, Biliary reflux, International Society, Medtech, Pharmacoeconomics, Anatomy, Technology, University of York, AG, Magnetism, PPI, Standard of care, Conference, Patient, CEO, Payment, Insurance, Medical device

), a MedTech company at the forefront of bringing advanced technology into the body, attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference Europe 2022 that was held 6-9 November, in Vienna, Austria and Virtual #ISPOREurope.

Key Points: 
  • ), a MedTech company at the forefront of bringing advanced technology into the body, attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference Europe 2022 that was held 6-9 November, in Vienna, Austria and Virtual #ISPOREurope.
  • ISPOR isthe leading European conference for Health Economics and Outcomes Research (HEOR) held for discussion and dissemination of the latest trends in healthcare.
  • Implantica presented on the health economic impact of RefluxStopTMa new surgical solution that corrects the anatomy of the body to resolve the cause of acid reflux.
  • "Implantica presented our very positive economic impact results: RefluxStop provides higher quality of life than the competing treatments by providing better symptom control with fewer side effects.